Over 12 months, Crescent Biopharma, Inc. saw more buying than selling from its insiders — purchases of about $30.6 million against sales of $1.5 million.
The largest purchase came from Harwin Peter Evan (Director), about $18.2 million.
On the institutional side, 80 funds reported holding CBIO at the end of Q2 2026, and more funds bought than sold. Quarter by quarter: Last full quarter: net buying by insiders. Insiders bought in 2 of the last 7 full quarters.
| Filed | Insider | Role | Type | Shares | Price | Value | Source |
|---|---|---|---|---|---|---|---|
| Sep 18, 2026 | Lynch Ryan | Officer | Sell | 240 | $17.90 | $4K | SEC |
| Sep 18, 2026 | Pinkas Jan | Executive Officer | Sell | 658 | $17.90 | $12K | SEC |
| Sep 18, 2026 | Im Ellie Eunkyung | Executive Officer | Sell | 623 | $17.90 | $11K | SEC |
| Sep 18, 2026 | Scalzo Richard William | CFO | Sell | 568 | $17.90 | $10K | SEC |
| Sep 18, 2026 | Bispham Barbara Harlin | Officer | Sell | 620 | $17.90 | $11K | SEC |
| Sep 18, 2026 | Brumm Joshua T | CEO | Sell | 1,610 | $17.90 | $29K | SEC |
| Sep 18, 2026 | Brumm Joshua T | CEO | Sell | 7,837 | $16.71 | $131K | SEC |
| Sep 18, 2026 | McNeill Jonathan | COO | Sell | 731 | $17.90 | $13K | SEC |
| Sep 18, 2026 | McNeill Jonathan | COO | Sell | 3,839 | $16.71 | $64K | SEC |
| Jul 20, 2026 | Fairmount Healthcare Fund II L.P. | Director | Buy | 853,450 | $14.50 | $12.4M | SEC |
| Jun 23, 2026 | Lynch Ryan | Officer | Sell | 465 | $17.99 | $8K | SEC |
| Jun 23, 2026 | Pinkas Jan | Executive Officer | Sell | 1,288 | $17.99 | $23K | SEC |
| Jun 23, 2026 | Scalzo Richard William | CFO | Sell | 1,112 | $17.99 | $20K | SEC |
| Jun 23, 2026 | Bispham Barbara Harlin | Officer | Sell | 1,218 | $17.99 | $22K | SEC |
| Jun 23, 2026 | Im Ellie Eunkyung | Executive Officer | Sell | 1,219 | $17.99 | $22K | SEC |
In the last 12 months Crescent Biopharma, Inc. insiders made open-market purchases worth about $30.6 million and sales worth about $1.5 million. Data comes from SEC Form 4 filings, updated every 30 minutes on CapitalSnitch.
The most recent open-market insider trade in CBIO was filed on 2026-09-18.
80 investment managers reported holding CBIO in SEC Form 13F filings for Q2 2026.
No congressional trades in CBIO were reported in the past two years. The full list is free on CapitalSnitch.
Public-record data for research and education, not investment advice. Insider sales are often pre-planned (10b5-1). Congress data: Data derived from public disclosures filed under the Ethics in Government Act and the STOCK Act, republished free for public transparency and news reporting. Disclosures may lag the trade by 45 days or more and show amounts only as ranges. This data may not be used for credit rating, loan underwriting, solicitation of money (political, charitable or other), direct-mail or commercial targeting (5 U.S.C. 13107).